Jiangsu DiSano Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise integrating drug research and development, production and sales. It was established in October 2006 with a registered capital of 100 million yuan. The company has been successively recognized as a high-tech enterprise, a provincial specialized and specialized enterprise, a provincial enterprise technology center, a provincial postdoctoral innovation practice base, and a municipal drug consistency evaluation engineering technology research center. The company currently has small-capacity injection workshop, freeze-dried powder injection workshop, solid preparation workshop, external preparation workshop and supporting traditional Chinese medicine extraction and raw material workshop. All workshops and production lines have passed GMP certification.

The company has a rich product portfolio and has more than 90 approval documents for various types of drugs. The production license covers small-volume injections, lyophilized powder injections, tablets, hard capsules, lotions, tinctures, raw materials, etc. The company focuses on and deeply engaged in drug research and development and production in the fields of cardiovascular and cerebrovascular and dermatology. The leading products include Labellol series (trade name Behe), selenium disulfide lotion (trade name Hillsheng), and in domestic subdivided fields The share is at the forefront and the domestic market share of single products ranks at the forefront. In addition, the company's specialty products sterilized injection water is in a leading position in the field of vaccine diluents, with a market share of more than 80%, and is the main supplier of domestic vaccine companies.

The company attaches importance to and implements a long-term development strategy, adheres to the main development direction of cardiovascular and cerebrovascular and dermatological drugs, and takes refined operations in segmented markets as the core competitiveness. It enriches product pipelines through independent research and development and technical cooperation, and gains market competitive advantages. The company has become a comprehensive pharmaceutical company with unique characteristics in the sub-sectors.